COMP 2001

A randomised clinical trial investigating the effect of out of hospital Enoxaparin versus standard prophylaxis in THR or TKR

1 Treatments

Studied treatment
65279; in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 27-29 days

Control treatment
Enoxaparin 30 mg twice a day for 7-10 days

Concomitant treatments
-

2 Patients

Patients
THR or TKR

Inclusion criteria
-

Exclusion criteria
-

3 Methods

Blinding
-

Design
-

Centers
-

Geographical area
-

Sample size
873 (441/432)

ArretTrt1
-

ArretTrt0
-

PeriodeInclusion
-

Hypothese
-
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>symptomatic deep vein thrombosis</td>
<td>2/441</td>
<td>8/432</td>
<td>0,24</td>
<td>[0,05; 1,16]</td>
</tr>
<tr>
<td>Proximal deep vein thrombosis</td>
<td>30/1047</td>
<td>78/854</td>
<td>0,31</td>
<td>[0,20; 0,48]</td>
</tr>
<tr>
<td>DVT (asymptomatic or symptomatic)</td>
<td>-/1047</td>
<td>-/854</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Minor bleeding</td>
<td>10/441</td>
<td>10/432</td>
<td>0,98</td>
<td>[0,40; 2,38]</td>
</tr>
<tr>
<td>All VTE</td>
<td>-/1047</td>
<td>-/854</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>0/441</td>
<td>1/432</td>
<td>0,33</td>
<td>[0,01; 8,04]</td>
</tr>
<tr>
<td>Symptomatic venous thromboembolism</td>
<td>2/441</td>
<td>10/432</td>
<td>0,23</td>
<td>[0,06; 0,93]</td>
</tr>
<tr>
<td>Death</td>
<td>0/441</td>
<td>1/432</td>
<td>0,33</td>
<td>[0,01; 8,04]</td>
</tr>
<tr>
<td>Symptomless venous thromboembolism</td>
<td>49/315</td>
<td>69/298</td>
<td>0,67</td>
<td>[0,45; 1,01]</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>0/441</td>
<td>2/432</td>
<td>0,20</td>
<td>[0,01; 4,09]</td>
</tr>
<tr>
<td>Distal deep vein thrombosis</td>
<td>37/315</td>
<td>41/298</td>
<td>0,85</td>
<td>[0,53; 1,37]</td>
</tr>
</tbody>
</table>

5 References


6 Comments